Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Filters applied: . Clear all
Page 1
Pancreas transplantation in type 1 diabetes: hope vs reality.
Mayes JT, Dennis VW, Hoogwerf BJ. Mayes JT, et al. Cleve Clin J Med. 2000 Apr;67(4):281-6. doi: 10.3949/ccjm.67.4.281. Cleve Clin J Med. 2000. PMID: 10780100 Free article. Review.
Increasing evidence suggests that it may slow the progression of long-term diabetic complications. On the other hand, patients risk the adverse effects of lifelong immunosuppression....
Increasing evidence suggests that it may slow the progression of long-term diabetic complications. On the other hand, patients risk t …
Inhibition of anti-OKT3 antibody generation by cyclosporine--results of a prospective randomized trial.
Hricik DE, Mayes JT, Schulak JA. Hricik DE, et al. Among authors: mayes jt. Transplantation. 1990 Aug;50(2):237-40. doi: 10.1097/00007890-199008000-00013. Transplantation. 1990. PMID: 2200174 Clinical Trial.
Rejection was reversed in 96% of patients in group 1 and in only 75% of patients in group 2 (P less than 0.03), suggesting that continued administration of reduced doses of CsA during therapy with OKT3 improves the short-term response to this monoclonal antibody. Results o …
Rejection was reversed in 96% of patients in group 1 and in only 75% of patients in group 2 (P less than 0.03), suggesting that continued ad …
Potent immunosuppression overcomes immunologic high-risk factors in recipients of cadaveric renal allografts.
Gaber AO, Thistlethwaite JR Jr, Haag BW, Stuart JK, Mayes JT, Lloyd DM, Fellner S, Stuart FP. Gaber AO, et al. Among authors: mayes jt. Am Surg. 1987 Jul;53(7):407-9. Am Surg. 1987. PMID: 3300451
In addition, most also received a short posttransplant course of antilymphocyte globulin and long-term azathioprine. With these regimens, retransplantation, sensitization, current B-cell crossmatch and historical B- and/or T-cell crossmatch do not affect graft survival....
In addition, most also received a short posttransplant course of antilymphocyte globulin and long-term azathioprine. With these regim …